Business Context and Reporting Period
This Form 8-K, dated September 15, 2011, reports on the consummation of a business combination (the "Merger") between Alkermes, Inc. and the drug technologies business of Elan Corporation, plc ("EDT"). The combined entity operates under the name Alkermes plc (formerly Antler Science Two plc). The report details the immediate resignation of the prior board of directors and the appointment of new executive officers and directors effective September 16, 2011.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, or debt metrics for the combined entity. Financial data is limited to specific executive compensation terms:
- Shane Cooke (President): Annual base salary of EUR 444,500; target performance pay of 75% of base salary; monthly car benefit of EUR 2,000; retirement contribution of 23.55% of base salary.
- James Botkin (SVP, Operations): Annual base salary of $380,000; target performance pay of 50% of base salary.
- Equity Grants: Mr. Cooke received options for 350,000 shares and 50,000 restricted stock units. Mr. Botkin received options for 100,000 shares.
Material Changes
The primary material change is the corporate restructuring resulting from the Merger. Key changes include:
- Board Resignations: Directors Nigel Clerkin and William F. Daniel resigned immediately upon the effective time of the Merger.
- Executive Appointments: Richard F. Pops was appointed CEO; Shane Cooke was appointed President; James M. Frates was appointed Senior Vice President & CFO.
- Director Appointments: Eight new directors were appointed, including Richard F. Pops, David W. Anstice, and Floyd E. Bloom.
- Compensation Plans: Adoption of the Fiscal 2012 Performance Pay Plan and the Amended 2008 Stock Option and Incentive Plan to align with the new corporate structure.
Guidance, Outlook, and Risks
The filing outlines specific performance objectives for the Fiscal 2012 Performance Pay Plan, which serve as management's strategic priorities:
- Successfully launch VIVITROL into the opioid indication.
- Execute on the expanded development of the late-stage product portfolio.
- Rapidly advance the emerging proprietary pipeline.
- Complete the acquisition of Elan Drug Technologies and execute an integration plan.
- Achieve financial performance against guidance.
Risks and Contingencies: The filing details significant severance obligations for executives in the event of termination without cause or "good reason," including payments of 1.5x base salary plus average bonus over 18 months for Mr. Cooke and 1x base salary plus average bonus over 12 months for Mr. Botkin. Change in control provisions provide for lump-sum payments and continued health benefits.
Investor Verification Checklist
- Verify the final terms of the Merger agreement between Alkermes, Inc. and Elan Corporation, plc.
- Confirm the total number of shares reserved under the Amended 2008 Plan and the 2011 Plan.
- Review the specific financial guidance targets referenced in the Performance Pay Plan objectives.
- Assess the impact of the new executive compensation packages on future operating expenses.
- Monitor the integration progress of the Elan Drug Technologies business as outlined in the performance objectives.